Table 3. - Antifungal susceptibility of C. neoformans var. grubii isolates obtained before treatment and during the period refractory to treatment or during relapse of cryptococcosis from 19 patients with AIDS.
| Antifungal Drug | GROUP 1 | |||
|---|---|---|---|---|
|
| ||||
| Pretreatment | Relapse and/or refractory period | p value*** | ||
| Amphotericin B | MIC Range (µg/mL) | 0.13 - 0.50 | 0.13 - 0.50 | 0.8791 |
| MIC 50 (µg/mL)* | 0.25 | 0.25 | ||
| MIC 90 (µg/mL)* | 0.50 | 0.50 | ||
| G.M (µg/mL)** | 0.28 | 0.27 | ||
| Fluconazole | MIC Range (µg/mL) | 1.0 - 8.0 | 0.13 - 8.0 | 0.6290 |
| MIC 50 (µg/mL) | 4.0 | 4.0 | ||
| MIC 90 (µg/mL) | 4.0 | 8.0 | ||
| G.M (µg/mL) | 3.84 | 3.64 | ||
| Itraconazole | MIC Range (µg/mL) | 0.03 - 1.0 | 0.03 - 0.13 | 0.1973 |
| MIC 50 (µg/mL) | 0.06 | 0.06 | ||
| MIC 90 (µg/mL) | 0.25 | 0.13 | ||
| G.M (µg/mL) | 0.13 | 0.08 | ||
| Voriconazole | MIC Range (µg/mL) | 0.03 - 0.50 | 0.25 - 0.50 | 0.6102 |
| MIC 50 (µg/mL) | 0.25 | 0.25 | ||
| MIC 90 (µg/mL) | 0.50 | 0.50 | ||
| G.M (µg/mL) | 0.30 | 0.27 | ||
| Flucytosine | MIC Range (µg/mL) | 4.0 - 16.0 | 4.0 - 16.0 | 0.4888 |
| MIC 50 (µg/mL) | 8.0 | 8.0 | ||
| MIC 90 (µg/mL) | 16.0 | 8.0 | ||
| G.M (µg/mL) | 7.78 | 6.63 | ||
* MIC50 and MIC90. the concentrations capable of inhibiting the growth of 50% and 90% of the isolates, respectively, **GM: geometric means, ***p value, statistic.